Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States.
The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders.
Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 10, 24 | -1.21 Increased by +3.97% | -1.35 Increased by +10.37% |
| Mar 12, 24 | -1.34 Decreased by -22.94% | -1.37 Increased by +2.19% |
| Nov 6, 23 | -1.33 Decreased by -44.57% | -1.35 Increased by +1.48% |
| Aug 7, 23 | -1.27 Decreased by -12.39% | -1.34 Increased by +5.22% |
| May 4, 23 | -1.26 Decreased by -24.75% | -1.12 Decreased by -12.50% |
| Mar 3, 23 | -1.09 Decreased by -263.33% | -1.10 Increased by +0.91% |
| Nov 3, 22 | -0.92 Decreased by -5.75% | -1.23 Increased by +25.20% |
| Aug 4, 22 | -1.13 Decreased by -68.66% | -1.06 Decreased by -6.60% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 8.00 K Increased by +N/A% | -39.44 M Decreased by -107.12% | Decreased by -493.00 K% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -37.51 M Decreased by -57.56% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -32.74 M Decreased by -35.36% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -29.72 M Decreased by -328.24% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -19.04 M Increased by +6.18% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 100.00 K Increased by 0.00% | -23.80 M Decreased by -52.37% | Decreased by -23.80 K% Decreased by -52.37% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -24.19 M Decreased by -52.26% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 20.00 M Increased by +N/A% | -6.94 M Increased by +34.99% | Decreased by -34.70% Decreased by N/A% |